02:04 PM EDT, 03/15/2024 (MT Newswires) -- Johnson & Johnson's ( JNJ ) cell therapy, Carvykti, for treating a specific form of blood cancer at an earlier stage got unanimous support for authorization by the advisers to the US Food and Drug Administration, Reuters reported Friday.

The 11-member voting panel agreed that the advantages of the therapy outweigh the risks as an early treatment.

The FDA and Johnson & Johnson ( JNJ ) didn't immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 158.13, Change: -1.08, Percent Change: -0.68